J Clin Oncol. 2024 Jun 25:JCO2400539. doi: 10.1200/JCO.24.00539. Online ahead of print.
ABSTRACT
Unlocking the full potential of clinical trials through comprehensive CSR and IPD sharing can revolutionize cancer care, enhance safety evaluations, and reduce bias in systematic reviews. It is time for all stakeholders to embrace transparency and advance patient-centered outcomes.
PMID:38917375 | DOI:10.1200/JCO.24.00539
